1. Field of the Invention
The disclosed embodiments relate to compositions, devices, and methods related to promoting blood clotting.
2. Description of the Related Art
Blood is a liquid tissue that includes red cells, white cells, corpuscles, and platelets dispersed in a liquid phase. The liquid phase is plasma, which includes acids, lipids, solubilized electrolytes, and proteins. The proteins are suspended in the liquid phase and can be separated out of the liquid phase by any of a variety of methods such as filtration, centrifugation, electrophoresis, and immunochemical techniques. One particular protein suspended in the liquid phase is fibrinogen. When bleeding occurs, the fibrinogen reacts with water and thrombin (an enzyme) to form fibrin, which is insoluble in blood and polymerizes to form clots.
In a wide variety of circumstances, wounds can be inflicted as the result of trauma. Often bleeding is associated with such wounds. In some circumstances, the wound and the bleeding are minor, and normal blood clotting functions in addition to the application of simple first aid are all that is required. First aid may include applying pressure to the wound with a sponge or similar device to facilitate clotting functions. Unfortunately, however, in other circumstances substantial bleeding can occur. Bleeding can also be a problem when the trauma is the result of a surgical procedure. Apart from suturing or stapling an incision or internally bleeding area, bleeding encountered during surgery is often controlled using sponges or other materials used to exert pressure against the bleed site and/or absorb the blood. However, in many circumstances these measures are not sufficient, such as when the bleeding becomes excessive, or when the wound is difficult to reach, or when it is advantageous to be able to view continuously the wound area.
Compositions comprising a clay, or a component of a clay, dispersed in a liquid medium can be useful as hemostatic or blood-clotting compositions or agents. These compositions may be useful for promoting the clotting of blood for animals or human beings, including clotting blood in individuals with a compromised ability to clot blood, such as individuals taking anticoagulant drugs such as heparin, warfarin, clopidogrel, coumarin, etc., or individuals suffering from clotting disorders such as Hemophilia A, Hemophilia B, von Willebrand disease, etc.
Some embodiments include a blood-clotting agent comprising: a composition comprising clay dispersed in a liquid medium, wherein the clay is less than about 10% by weight of the composition; and wherein the composition including the liquid medium and clay has a viscosity of about 1000 cP or less.
Some embodiments include a blood-clotting agent comprising: a composition comprising clay dispersed in a liquid medium, wherein the clay is less than about 10% by weight of the composition; and wherein the composition including the liquid medium and clay has a viscosity of about 1000 cP to about 100,000 cP.
Some embodiments include a hemostatic composition comprising: a clay dispersed in an aqueous medium; wherein the composition is a liquid which is substantially free of visible clay particles; and wherein the composition is sterilized.
Some embodiments comprise a hemostatic composition comprising: kaolin dispersed in an aqueous medium; wherein the composition is flowable; wherein at least 50% of the kaolin has a particle size in the range of about 1 nm to about 1000 nm; and wherein the composition is sterilized.
Some embodiments include a hemostatic device comprising: a vessel which contains a hemostatic composition of the type described herein; and a dispensing component in fluid communication with the vessel; wherein the device is configured so that the dispensing component is capable of dispensing the hemostatic composition from the vessel to a bleeding area of an animal or person.
Some embodiments comprise a hemostatic composition comprising: a liquid comprising a first component of a kaolin, wherein the first component of the kaolin is prepared by a process comprising: dispersing the kaolin in an aqueous medium; and separating the first component of the kaolin from a second component of the kaolin; wherein the first component of the kaolin has an average particle size which is smaller than an average particle size of the second component of kaolin.
Some embodiments include a hemostatic composition comprising: a component of kaolin dispersed in an aqueous medium; wherein the component of kaolin is capable of remaining dispersed in the aqueous medium for at least about 60 minutes without agitation.
Some embodiments include a hemostatic composition comprising: a component of kaolin dispersed in an aqueous medium; wherein the component of kaolin is capable of remaining dispersed in the aqueous medium for at least about 5 minutes in a centrifuge at a centripetal acceleration of at least about 1000 m/s2.
Some embodiments include a blood-clotting composition comprising: a fine kaolin having a reduced particle size as compared to a particle size of a naturally and/or commonly occurring kaolin; and water; wherein the fine kaolin is dispersed in the water to form a stable kaolin-water dispersion.
Some embodiments include a hemostatic system comprising: a hemostatic device comprising: a vessel comprising an interior volume configured to contain a liquid; an orifice in fluid communication with the interior volume comprising a rim surrounding the orifice, wherein the rim is configured to form a seal, a removable adhesive connection, or a contact surface with a part of an animal body or a human body; a fluid input component configured to provide a liquid to the interior volume of the vessel; and a fluid output component configured to allow liquid to exit the interior volume of the vessel; and a composition of the type described herein.
As used herein, the term “hemostatic composition” is used in accordance with the ordinary meaning in the art and includes a blood-clotting agent, a blood-clotting composition, a hemostatic composition, a hemostatic agent, or a similar material. A hemostatic composition may comprise a clay or a component of a clay which may be dispersed in a liquid medium.
A liquid medium may include any liquid, including an aqueous liquid. In some embodiments, the liquid medium may contain at least: about 10%, about 50%, or about 90% water by weight. Other liquids, including organic liquids, may be used. For example, alcohols such as glycerin, ethanol, methanol, isopropanol, and the like, may also be used. A combination of non-aqueous liquids or a combination of water and other liquids may also be used. In some embodiments, tap water, saline water, distilled water, or sterile water may be used.
A clay may include any clay such as kaolin, bentonite, montmorillonite, saponite, polygorskite or attapulgite, sepiolite, etc. In some embodiments, the clay may be a kaolin clay, which may include the mineral “kaolinite.” The kaolin may include Edgar's plastic kaolin (hereinafter “EPK”), which is a water-washed kaolin clay that is mined and processed around Edgar, Fla.
A hemostatic composition may be prepared by adding an appropriate amount of clay to a liquid. This mixture may be used with these constituents by themselves and/or without further treatment or processing (besides possibly sterilization). In some embodiments, the mixture may be subjected to a separation process which may produce a separation of the clay into components or may provide clay particles in particular ranges of sizes. Thus, in some embodiments, one or more components or particular size ranges of clay may be used in addition to or in place of a native or standard type of clay. The component or particular size range of clay may be obtained by a separation process or may be separately obtained and added to a liquid. As used herein, unless otherwise indicated, the term “clay” should be understood to include clay, a component of clay, or a combination thereof.
In some embodiments, a first component of a clay may be separated from a second component of a clay. One or more separation processes may further provide additional components of the clay, such as a third component, a fourth component, etc. An example of a method that may be used to accomplish a separation may be dispersing a clay in a liquid, and then separating the dispersion by filtration or using one or more settling methods such as centrifugation or standing.
A separation may produce a first component which is distinct from other components in some way. Some separations involve separating a fraction which has more liquid from a fraction which has more solid, as compared to the composition before the separation is carried out. A liquid fraction may include a supernatant, or the liquid portion removed from the top of a centrifuged mixture, or a filtrate, or the liquid which is passed through a filter during a filtration. A solid fraction may include the sediment or solid material from a centrifugation or the filtered solid material obtained by filtration. In some embodiments, a first component of a clay is separated from a second component of a clay by centrifuge or filtration.
In some embodiments, a first component may consist essentially of or include higher levels of ions of calcium (e.g. Ca+, Ca2+, etc.), aluminum (e.g. Al+, Al2+, Al3+, etc.), iron (e.g. Fe+, Fe2+, Fe3+, etc.) magnesium (e.g. Mg+, Mg2+, etc.), potassium (e.g. K+), sodium (e.g. Na+), or other ions. If the first component comprises a liquid fraction, this may be because the ions are soluble in the liquid, and thus retained with the liquid fraction. For example, the molar ratio of one or more of these ions in a first component as compared to a second component may be at least about 1.1, about 2, or about 5 to about 10, about 100, or about 1000. Ions such as those listed above may also be added directly to the composition.
In some embodiments, a first component may have an average particle size which is smaller than the average particle size of a second component or another component of the clay.
While a clay may be present in any amount, a clay may be at least: about 0.00001%, about 0.001%, or about 0.01% by weight of the composition, and/or may further be about 10% or less, about 5% or less, or about 1% or less by weight of the composition. In some embodiments, a hemostatic composition may include clay particles of a size that renders the composition substantially free of visible clay particles to an observer with an unaided eye. In some embodiments, the turbidity of the composition may be at least: about 0.001 Nephelometric Turbitidy Units (NTU), about 0.01 NTU, or about 0.3 NTU, and/or may further be about 5 or less, about 50 or less, or about 200 or less. In some embodiments, the clay may be dispersed in a liquid to provide a stable clay-liquid dispersion, such as a stable clay-water dispersion or kaolin-water dispersion. In some embodiments, an appreciable amount of the clay particles may not settle from an aqueous liquid upon standing. In some embodiments, the clay particles may not settle from an aqueous liquid upon standing for at least about 5 minutes, at least about 1 hour, at least about 12 hours, at least about 1 day, at least about 1 month, or at least about 1 year. In some embodiments, the clay particles may be capable of remaining dispersed in an aqueous liquid for at least about 1 minute, at least about 5 minutes, at least about 30 minutes, or at least about an hour in a centrifuge at a centripetal acceleration of at least about 100 m/s, at least about 1000 m/s, or at least about 10,000 m/s.
A clay may have a particle size in a range that allows it to be dispersed in the liquid. For example, in some embodiments, at least about 50%, at least about 90%, or at least about 95% of a clay, such as kaolin, may have a particle size in the range of about 1 nm to about 10 μm, about 10 nm to about 5 μm, or about 50 nm to about 5 μm. In some embodiments, a fine clay may be used which has a reduced particle size as compared to a particle size of a naturally and/or commonly occurring clay. In some embodiments, the fine clay may be fine kaolin.
Tonicity agents may be included or omitted in a hemostatic composition to adjust tonicity, for example, to make the composition isotonic, hypertonic, or hypotonic. Tonicity may be adjusted by adjusting the concentration of a tonicity agent. For example, reducing the concentration of a tonicity agent may reduce the tonicity of the composition, and increasing the concentration of a tonicity agent may increase the tonicity of the composition. Suitable tonicity agents include, but are not limited to, sugars, such as glucose and isomers thereof, dextrose, fructose and isomers thereof, disaccharides, etc.; alkali salts (e.g. Group I salts), such as salts of Na+, K+, etc.; halide salts, such as salts of Cl−, Br−, I−, etc.; polyols such as glycerin and other sugar alcohols such as mannitol, sorbitol, etc.; etc.
A hemostatic composition may be sterile or sterilized. An antimicrobial agent may be included in some embodiments, which may help to preserve the sterility of a composition over time, or may help to improve or preserve the sterility of the bleeding area while a hemostatic composition is used to promote clotting of a wound. Suitable antimicrobial agents may include, but are not limited to, compounds or salts containing silver ions; compounds or salts containing copper ions; and halogen-based antimocrobials such as iodine, bromine, and chlorine, and salts or oxides thereof, such as ClO−, BrO−, IO−, etc. In some embodiments, the antimicrobial agent may comprise a stabilized halogen or halogen containing salt. One example of an antimicrobial agent includes povidone (also known as polyvinylpyrrolidone) and/or iodine, such as a 10% povidone iodine solution.
A hemostatic composition may comprise a therapeutically active agent. Examples of therapeutically active agents may include, but are not limited to, analgesics, including but not limited to, opiates such as codeine, morphine, oxycodone, etc.; acetaminophen; anti-inflammatory agents, including nonsteroidal anti-inflammatory drugs, aspirin, etc.; antibiotics or another antimicrobial drugs or compounds; antihistamines (e.g., cimetidine, chloropheniramine maleate, diphenhydramine hydrochloride, and promethazine hydrochloride); antifungal agents; ascorbic acid; tranexamic acid; rutin; thrombin; botanical agents; etc.; and combinations thereof. Other additives may include magnesium sulfate, sodium metaphosphate, calcium chloride, dextrin, and combinations thereof.
A hemostatic agent may be in any form, such as a liquid, a gel, a paste, a foam, a cream, a particle, a powder, or other form. In some embodiments, a hemostatic composition may be flowable. For example, a hemostatic composition may have a viscosity from at least: about 0.1 cP, about 0.2 cP, about 0.5 cP, about 1 cP; and/or less than or equal to: about 1000 cP, about 10,000 cP, or about 100,000 cP. The viscosity may vary according to the type of injury or situation in which the composition is used and/or the form of the composition. For example, in some embodiments, a liquid with a viscosity similar to water, such as a viscosity at or below about 1000 cP, about 100 cP, or about 10 cP, may be desired for surgical applications. In some situations, such as in treating a wound formed by a bullet or another type of penetrating wound, a form of composition that is thicker or more viscous than water may be used, such as a gel or foam, to allow the composition to generally plug up or generally fill or generally obstruct or generally impede communication between the internal injured area and the area outside of the body to diminish the egress of blood from the wound and the ingress of contaminants into the wound. The composition may, in some instances, have much higher viscosities, such as at least: about 1000 cP, about 10,000 cP, or about 50,000 cP; and/or less than or equal to: about 100,000 cP, about 150,000 cP, or about 250,000 cP.
For some forms of thicker or more viscous compositions, such as gels, pastes, foams, or other forms, a thickening agent, such as a gelling agent, may be added to increase the viscosity of the liquid. The thickening agent may also help to keep a hemostatic agent such as a clay from settling from the dispersion. Any thickening agent may be used, including, but not limited to, cellulose derivatives such as carboxymethylcellulose, hydroxypropylmethylcellulose, methylcellulose, hydroxypropylcellulose, etc.; other carbohydrates or polysaccharides, or derivatives thereof, such as dextrans, starches, starch derivatives, carrageenan, guar gum, gum karaya, xanthan gum, gum arabic, gum tragacanth, etc.; polycarboxylic acids such as polyacrylic acid, polymethacrylic acid, etc.; fatty acids such as myristic acid, palmitic acid, stearic acid, arachidic acid, and behenic acid, palmitoleic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, arachidonic acid, eicosapentaenoic acid, etc.; polyalkylene glycol polymers or copolymers such as polyethylene glycol, polyethylene glycol-polypropylene glycol copolymers, etc.
A hemostatic composition may also contain cations such as calcium (e.g. Ca+, Ca2+, etc.), aluminum (e.g. Al+, Al2+, Al3+, etc.), iron (e.g. Fe+, Fe2+, Fe3+, etc.) magnesium (e.g. Mg+, Mg2+, etc.), potassium (e.g. K+), sodium (e.g. Na+), silver, etc.
A hemostatic composition may be applied to any bleeding area of an animal or human being. Examples of injuries which may involve bleeding which could be treated with a hemostatic composition include, but are not limited to, injuries related to surgery, injuries caused by a weapon such as a bullet, a blade such as a knife, sword or bayonet, an explosive weapon, etc.
In some situations, such as in treating an injury characterized by a generally long, generally tube-shaped bleeding hole (e.g., a bullet track or an injury caused by a biopsy), treatment may be accomplished by applying slightly more pressure to the infused hemostatic liquid than that of the exiting blood to position the hemostatic material at a suitable location within or proximate to the injury to assist in diminishing or halting bleeding. For example, the pressure may be at least: about 180 mmHg, about 200 mmHg, about 250, about 300 mmHg; and/or less than or equal to: about 500 mmHg, about 700 mmHg, or about 1000 mmHg. In some embodiments, the pressure may be about 300 mmHg.
The term “vessel” is used herein in accordance with its ordinary meaning in the art and includes any structure which is capable of holding a hemostatic composition and being in fluid communication with a dispensing component. Examples may include, but are not limited to, containers such as bottles, vials, canisters, tubes, reservoirs, etc., and materials which may hold the composition such as a sponge, a cloth, a gauze, etc. A dispensing component may be any feature which is capable of being in fluid communication with a vessel and dispensing a hemostatic composition from the vessel to a bleeding area of an animal or person. Examples may include, but are not limited to, valves, lumens, orifices, pumps, sponges, cloths, etc. In some embodiments, a hemostatic device may comprise an absorbent material, such as a sponge, cloth, gauze, etc., wherein a liquid hemostatic composition is absorbed therein. The absorbent material may be saturated, meaning that the material cannot absorb any more liquid, or it may contain a liquid hemostatic composition but not be saturated. These devices may be further packaged in a film or other sealing material to reduce evaporation or other loss of the liquid.
A hemostatic composition may be dispensed by and/or incorporated into a hemostatic device.
As shown in
A hemostatic composition may be incorporated into other systems or methods in many different types of various applications, such as surgery. These methods or systems may comprise a hemostatic composition in liquid form (or a “hemostatic liquid”) and a liquid provision component configured to provide the hemostatic liquid to an area of a human being or animal affected by a surgical procedure, such as an area that is bleeding as a result of a surgical procedure. The liquid provision component may be any structure, component, or device which is capable of providing the hemostatic liquid to the area affected by a surgical procedure (e.g., through irrigation). For example, the hemostatic liquid may be provided during surgery, while surgery is being completed, after surgery is completed, etc. Examples may include, but are not limited to, surgical tubing with a hand piece comprising a valved dispensing portion to permit selective dispensing or irrigation. A system or method may further comprise a liquid-removal component configured to remove liquids, such as the hemostatic liquid, blood, or other liquids, from the area of the human being or animal affected by the surgical procedure (e.g., through aspiration). The liquid-removal component may be any structure, component, or device which is capable of removing liquid from the area affected by a surgical procedure. Examples may include, but are not limited to, tubing, such as surgical tubing. The liquid removal component may further be configured to remove the hemostatic liquid while the surgery is taking place, as surgery is being completed, after surgery is completed, etc. The liquid-delivery and liquid-removal components can be included together on a single hand piece or can be provided separately. An actuator positioned on the hand piece or surgical tubing can activate either or both of the irrigation and aspiration features, or toggle between them.
In some embodiments, a hemostatic system may comprise a hemostatic device that may comprise a vessel and a hemostatic composition. The vessel may be any vessel which is configured to contain a liquid. This vessel may further comprise an interior volume configured to contain a liquid, and an orifice in fluid communication with the interior volume comprising a rim surrounding the orifice, wherein the rim is configured to generally provide contact with or to generally form a seal with a part of an animal body or a human body.
A rim may be a rim similar to a rim of a cup or a glass, or it may simply be formed by a hole on an external surface of the vessel. It may be even with an external surface of the vessel or may be raised with respect to the surface of the vessel. In some embodiments, the rim may be flexible or resilient. A seal may be formed by causing the rim to be pressed against the body part and/or by disposing an adhesive material on the rim so that a seal is formed by temporary adhesion between the rim and the body part.
A vessel may further comprise a fluid input component configured to provide a liquid to an interior volume of the vessel. The fluid input component may be any structural feature or combination of features which may provide a liquid to an interior volume of a vessel, such as an orifice or a valve.
A vessel may further comprise a fluid output component configured to allow liquid to exit from the vessel. The fluid output component may be any structural feature or combination of features which may allow liquid to exit from the vessel, such as an orifice or a valve.
Kaolin (about 0.34 g) and glycerin (about 0.91 g) are mixed with sterile, distilled, non pyrogenic, pH 7.0 water (about 42 mL). The mixture appears cloudy or turbid.
The mixture of Example 1 is centrifuged for about 5 minutes at about 3000 rpm. The supernatant is carefully collected and the precipitate is discarded to yield a liquid hemostatic composition which appears substantially clearer.
The composition of Example 2 (about 3 mL) is combined with 10% povidone iodine (about 3 mL).
The composition of Example 2 (about 6 mL) is combined with 10% povidone iodine (about 3 mL).
The compositions prepared as described in Examples 1-3, and water were tested for clotting. The test was carried out by combining 0.5 ml of the hemostatic composition with 1 ml of citrated sheep blood and 150 μL of CaCl2 in a test tube.
The clotting times for the four samples are shown in Table 1 below.
Although the embodiments have been described in the context of certain examples, it will be understood by those skilled in the art that the scope of the claims may extend beyond the specifically disclosed embodiments to other embodiments including embodiments formed of combinations of features disclosed herein and equivalents thereof.
This application claims the benefit of U.S. Provisional Application No. 61/385,388, filed Sep. 22, 2010, which is incorporated by reference herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2688586 | Eberl et al. | Sep 1954 | A |
2969145 | Hannuer, Jr. | Jan 1961 | A |
3122140 | Crowe et al. | Feb 1964 | A |
3181231 | Breck | May 1965 | A |
3189227 | Hobbs et al. | Jun 1965 | A |
3366578 | Michalko | Jan 1968 | A |
3386802 | Michalko | Jun 1968 | A |
3538508 | Young | Nov 1970 | A |
3550593 | Kaufman | Dec 1970 | A |
3658984 | Kamp | Apr 1972 | A |
3698392 | Vogt et al. | Oct 1972 | A |
3723352 | Warner et al. | Mar 1973 | A |
3763900 | Solms-Baruth et al. | Oct 1973 | A |
3979335 | Golovko et al. | Sep 1976 | A |
4373519 | Errede et al. | Feb 1983 | A |
4374044 | Schaefer et al. | Feb 1983 | A |
4379143 | Sherry et al. | Apr 1983 | A |
4435512 | Ito et al. | Mar 1984 | A |
4460642 | Errede et al. | Jul 1984 | A |
4514510 | Alexander | Apr 1985 | A |
4524064 | Nambu | Jun 1985 | A |
4525410 | Hagiwara et al. | Jun 1985 | A |
4569343 | Kimura et al. | Feb 1986 | A |
4626550 | Hertzenberg | Dec 1986 | A |
4631845 | Samuel et al. | Dec 1986 | A |
4651725 | Kifune et al. | Mar 1987 | A |
4717735 | Strem | Jan 1988 | A |
4728323 | Matson | Mar 1988 | A |
4748978 | Kamp | Jun 1988 | A |
4822349 | Hursey et al. | Apr 1989 | A |
4828081 | Nordstrom et al. | May 1989 | A |
4828832 | De Cuellar et al. | May 1989 | A |
4911898 | Hagiwara et al. | Mar 1990 | A |
4938958 | Niira et al. | Jul 1990 | A |
4956350 | Mosbey | Sep 1990 | A |
5140949 | Chu et al. | Aug 1992 | A |
5146932 | McCabe | Sep 1992 | A |
5474545 | Chikazawa | Dec 1995 | A |
5486195 | Myers et al. | Jan 1996 | A |
5502042 | Gruskin et al. | Mar 1996 | A |
5538500 | Peterson | Jul 1996 | A |
5556699 | Niira et al. | Sep 1996 | A |
5578022 | Scherson et al. | Nov 1996 | A |
5597581 | Kaessmann et al. | Jan 1997 | A |
5599578 | Butland | Feb 1997 | A |
D386002 | Hinkle | Nov 1997 | S |
5696101 | Wu et al. | Dec 1997 | A |
5716337 | McCabe et al. | Feb 1998 | A |
5725551 | Myers et al. | Mar 1998 | A |
5728451 | Langley et al. | Mar 1998 | A |
5766715 | Garconnet | Jun 1998 | A |
5788682 | Maget | Aug 1998 | A |
5801116 | Cottrell et al. | Sep 1998 | A |
5826543 | Raymond et al. | Oct 1998 | A |
5855570 | Scherson et al. | Jan 1999 | A |
5916511 | Kotani et al. | Jun 1999 | A |
5941897 | Myers | Aug 1999 | A |
5964239 | Loux et al. | Oct 1999 | A |
5964349 | Odagiri | Oct 1999 | A |
5981052 | Sugiyama | Nov 1999 | A |
5993964 | Nakajima | Nov 1999 | A |
6037280 | Edwards et al. | Mar 2000 | A |
6060461 | Drake | May 2000 | A |
6086970 | Ren | Jul 2000 | A |
6123925 | Barry et al. | Sep 2000 | A |
6159232 | Nowakowski | Dec 2000 | A |
6187347 | Patterson et al. | Feb 2001 | B1 |
6203512 | Farris et al. | Mar 2001 | B1 |
6251423 | Bradford | Jun 2001 | B1 |
6372333 | Sugiyama et al. | Apr 2002 | B1 |
6428800 | Greenspan et al. | Aug 2002 | B2 |
6450537 | Norris | Sep 2002 | B2 |
6475470 | Kayane et al. | Nov 2002 | B1 |
6481134 | Aledo | Nov 2002 | B1 |
6486285 | Fujita | Nov 2002 | B2 |
6495367 | Isogawa et al. | Dec 2002 | B1 |
6523778 | Key et al. | Feb 2003 | B2 |
6573419 | Naimer | Jun 2003 | B2 |
6590337 | Nishikawa et al. | Jul 2003 | B1 |
6622856 | Gallo et al. | Sep 2003 | B2 |
6630140 | Grunstein | Oct 2003 | B1 |
6685227 | Merry et al. | Feb 2004 | B2 |
6700032 | Gray | Mar 2004 | B1 |
6701649 | Brosi | Mar 2004 | B1 |
6745720 | Rasner et al. | Jun 2004 | B2 |
6890177 | Dragan | May 2005 | B2 |
6998510 | Buckman et al. | Feb 2006 | B2 |
7125821 | Xu et al. | Oct 2006 | B2 |
7303759 | Mershon | Dec 2007 | B2 |
7371403 | McCarthy et al. | May 2008 | B2 |
7429252 | Sarangapani | Sep 2008 | B2 |
7595429 | Hursey | Sep 2009 | B2 |
7604819 | Huey et al. | Oct 2009 | B2 |
7825133 | Yi | Nov 2010 | B2 |
7858123 | Stucky | Dec 2010 | B2 |
7968114 | Huey et al. | Jun 2011 | B2 |
8063264 | Spearman et al. | Nov 2011 | B2 |
8114433 | Huey et al. | Feb 2012 | B2 |
8202532 | Huey et al. | Jun 2012 | B2 |
8252318 | Huey et al. | Aug 2012 | B2 |
8252344 | Hursey | Aug 2012 | B2 |
8257731 | Horn et al. | Sep 2012 | B2 |
8257732 | Huey et al. | Sep 2012 | B2 |
8277837 | Fischer et al. | Oct 2012 | B2 |
8383148 | Huey et al. | Feb 2013 | B2 |
8460699 | Huey et al. | Jun 2013 | B2 |
8512743 | Horn et al. | Aug 2013 | B2 |
20020077653 | Hudson et al. | Jun 2002 | A1 |
20020197302 | Cochrum et al. | Dec 2002 | A1 |
20030018357 | Luthra et al. | Jan 2003 | A1 |
20030133990 | Hursey et al. | Jul 2003 | A1 |
20030175333 | Shefer et al. | Sep 2003 | A1 |
20030176828 | Buckman et al. | Sep 2003 | A1 |
20030199922 | Buckman | Oct 2003 | A1 |
20030208150 | Bruder et al. | Nov 2003 | A1 |
20030212357 | Pace | Nov 2003 | A1 |
20040005350 | Looney et al. | Jan 2004 | A1 |
20040013715 | Wnek et al. | Jan 2004 | A1 |
20040038893 | Ladner et al. | Feb 2004 | A1 |
20040121438 | Quirk | Jun 2004 | A1 |
20040131820 | Turner et al. | Jul 2004 | A1 |
20040166172 | Rosati et al. | Aug 2004 | A1 |
20040166758 | Reichmann et al. | Aug 2004 | A1 |
20040169033 | Kuibira et al. | Sep 2004 | A1 |
20040243043 | McCarthy et al. | Dec 2004 | A1 |
20050023956 | Kwak et al. | Feb 2005 | A1 |
20050058721 | Hursey | Mar 2005 | A1 |
20050070693 | Hansen et al. | Mar 2005 | A1 |
20050074505 | Hursey | Apr 2005 | A1 |
20050107826 | Zhu et al. | May 2005 | A1 |
20050118230 | Hill et al. | Jun 2005 | A1 |
20050119112 | Pfenninger et al. | Jun 2005 | A1 |
20050137512 | Campbell et al. | Jun 2005 | A1 |
20050143689 | Ramsey, III | Jun 2005 | A1 |
20050147656 | McCarthy et al. | Jul 2005 | A1 |
20050246009 | Toner et al. | Nov 2005 | A1 |
20050248270 | Ghosh et al. | Nov 2005 | A1 |
20050249899 | Bonutti | Nov 2005 | A1 |
20060034935 | Pronovost et al. | Feb 2006 | A1 |
20060078628 | Koman et al. | Apr 2006 | A1 |
20060116635 | Van Heugten et al. | Jun 2006 | A1 |
20060121101 | Ladizinsky | Jun 2006 | A1 |
20060141018 | Cochrum et al. | Jun 2006 | A1 |
20060141060 | Hursey et al. | Jun 2006 | A1 |
20060159733 | Pendharkar et al. | Jul 2006 | A1 |
20060172000 | Cullen et al. | Aug 2006 | A1 |
20060178609 | Horn et al. | Aug 2006 | A1 |
20060193905 | Ehringer et al. | Aug 2006 | A1 |
20060211965 | Horn et al. | Sep 2006 | A1 |
20060211971 | Horn et al. | Sep 2006 | A1 |
20060271094 | Hudson et al. | Nov 2006 | A1 |
20060282046 | Horn et al. | Dec 2006 | A1 |
20070016152 | Karpowicz et al. | Jan 2007 | A1 |
20070031515 | Stucky et al. | Feb 2007 | A1 |
20070065491 | Huey et al. | Mar 2007 | A1 |
20070104768 | Huey et al. | May 2007 | A1 |
20070104792 | Jenkins | May 2007 | A1 |
20070134293 | Huey et al. | Jun 2007 | A1 |
20070142783 | Huey et al. | Jun 2007 | A1 |
20070154509 | Wilcher et al. | Jul 2007 | A1 |
20070154510 | Wilcher et al. | Jul 2007 | A1 |
20070154564 | Stucky et al. | Jul 2007 | A1 |
20070160638 | Mentkow et al. | Jul 2007 | A1 |
20070160653 | Fischer et al. | Jul 2007 | A1 |
20070167971 | Huey et al. | Jul 2007 | A1 |
20070251849 | Lo et al. | Nov 2007 | A1 |
20070275073 | Huey et al. | Nov 2007 | A1 |
20070276308 | Huey et al. | Nov 2007 | A1 |
20070276345 | Huey et al. | Nov 2007 | A1 |
20070281011 | Jenkins et al. | Dec 2007 | A1 |
20080027365 | Huey | Jan 2008 | A1 |
20080085300 | Huey et al. | Apr 2008 | A1 |
20080097271 | Lo et al. | Apr 2008 | A1 |
20080125686 | Lo | May 2008 | A1 |
20080146984 | Campbell et al. | Jun 2008 | A1 |
20080199539 | Baker et al. | Aug 2008 | A1 |
20080206134 | Lo et al. | Aug 2008 | A1 |
20080254146 | Huey et al. | Oct 2008 | A1 |
20080254147 | Huey et al. | Oct 2008 | A1 |
20080269658 | Vinton et al. | Oct 2008 | A1 |
20080299226 | Mentkow et al. | Dec 2008 | A1 |
20080317831 | Lo | Dec 2008 | A1 |
20080319476 | Ward et al. | Dec 2008 | A1 |
20090008261 | Kotzeva et al. | Jan 2009 | A1 |
20090011394 | Meglan et al. | Jan 2009 | A1 |
20090018479 | McCarthy et al. | Jan 2009 | A1 |
20090043268 | Eddy et al. | Feb 2009 | A1 |
20090047366 | Bedard et al. | Feb 2009 | A1 |
20090053288 | Eskridge, Jr. et al. | Feb 2009 | A1 |
20090074880 | Ladizinsky | Mar 2009 | A1 |
20090076475 | Ross et al. | Mar 2009 | A1 |
20090112170 | Wells et al. | Apr 2009 | A1 |
20090123525 | Bedard | May 2009 | A1 |
20090162406 | Basadonna et al. | Jun 2009 | A1 |
20090186013 | Stucky et al. | Jul 2009 | A1 |
20090186071 | Huey et al. | Jul 2009 | A1 |
20090232902 | Liu et al. | Sep 2009 | A1 |
20090274769 | Fregonese | Nov 2009 | A1 |
20090299253 | Hursey | Dec 2009 | A1 |
20100035045 | McAmish | Feb 2010 | A1 |
20100121244 | Horn et al. | May 2010 | A1 |
20100184348 | McAmish | Jul 2010 | A1 |
20100209531 | Stucky et al. | Aug 2010 | A2 |
20100228174 | Huey et al. | Sep 2010 | A1 |
20100233248 | Huey et al. | Sep 2010 | A1 |
20110015565 | Hursey | Jan 2011 | A1 |
20110059287 | McAmish | Mar 2011 | A1 |
20110064785 | Daniels et al. | Mar 2011 | A1 |
20110150973 | Bowlin et al. | Jun 2011 | A1 |
20110229849 | Maurer et al. | Sep 2011 | A1 |
20110237994 | Russ et al. | Sep 2011 | A1 |
20110268784 | Huey | Nov 2011 | A1 |
20120004636 | Lo | Jan 2012 | A1 |
20120070470 | Pahari et al. | Mar 2012 | A1 |
20120130296 | Huey | May 2012 | A1 |
20120259262 | Huey | Oct 2012 | A1 |
20130041332 | Huey et al. | Feb 2013 | A1 |
20130079695 | Huey | Mar 2013 | A1 |
20130178778 | Huey et al. | Jul 2013 | A1 |
20130344131 | Lo | Dec 2013 | A1 |
Number | Date | Country |
---|---|---|
1223208 | Jun 1987 | CA |
101104080 | Jan 2008 | CN |
101541274 | Sep 2009 | CN |
101687056 | Mar 2010 | CN |
0 107 051 | Sep 1983 | EP |
0 296 324 | Dec 1988 | EP |
0 353 710 | Feb 1990 | EP |
0 826 822 | Mar 1998 | EP |
0 888 783 | Jul 1999 | EP |
1 159 972 | May 2001 | EP |
1 663 090 | Jun 2006 | EP |
1 690 553 | Aug 2006 | EP |
1 714 642 | Oct 2006 | EP |
1 810 697 | Jul 2007 | EP |
1 679 087 | Jan 2010 | EP |
2 142 220 | Jan 2010 | EP |
1 667 623 | Nov 2010 | EP |
2 077 811 | Nov 2010 | EP |
2 292 196 | Mar 2011 | EP |
2 259 858 | Mar 1993 | GB |
2 314 842 | Jan 1998 | GB |
2 462 228 | Feb 2010 | GB |
7088DELNP2009 | Apr 2008 | IN |
S59-62050 | Sep 1984 | JP |
01-096558 | Oct 1987 | JP |
2-45040 | Feb 1990 | JP |
9-504719 | May 1997 | JP |
10-337302 | Dec 1998 | JP |
11-071228 | Mar 1999 | JP |
11-178912 | Jul 1999 | JP |
11-332909 | Jul 1999 | JP |
2002-530157 | Sep 2002 | JP |
2002-331024 | Nov 2002 | JP |
2003-305079 | Oct 2003 | JP |
2005-015537 | Jan 2005 | JP |
WO 9505445 | Feb 1995 | WO |
WO 9512371 | May 1995 | WO |
WO 9640285 | Dec 1996 | WO |
WO 9913918 | Mar 1999 | WO |
WO 0030694 | Jun 2000 | WO |
WO 0066086 | Nov 2000 | WO |
WO 0182896 | Aug 2001 | WO |
WO 0197826 | Dec 2001 | WO |
WO 0230479 | Apr 2002 | WO |
WO 02060367 | Aug 2002 | WO |
WO 02074325 | Sep 2002 | WO |
WO 03074566 | Sep 2003 | WO |
WO 2005012493 | Feb 2005 | WO |
WO 2005027808 | Mar 2005 | WO |
WO 2005030279 | Apr 2005 | WO |
WO 2005087280 | Sep 2005 | WO |
WO 2005123170 | Dec 2005 | WO |
WO 2006006140 | Jan 2006 | WO |
WO 2006012218 | Feb 2006 | WO |
WO 2006086557 | Aug 2006 | WO |
WO 2006088912 | Aug 2006 | WO |
WO 2006102008 | Sep 2006 | WO |
WO 2006110393 | Oct 2006 | WO |
WO 2007120342 | Oct 2007 | WO |
WO 2008036225 | Mar 2008 | WO |
WO 2008054566 | May 2008 | WO |
WO 2008109160 | Sep 2008 | WO |
WO 2008127497 | Oct 2008 | WO |
WO 2008128149 | Oct 2008 | WO |
WO 2008136806 | Nov 2008 | WO |
WO 2008157536 | Dec 2008 | WO |
WO 2009032884 | Mar 2009 | WO |
WO 2009109194 | Sep 2009 | WO |
WO 2009126917 | Oct 2009 | WO |
Entry |
---|
Comparative Testing of Hemostatic Dressings in a Severe Groin Hemorrhage, Trauma & Resuscitative Medicine Department, NMRC, Aug. 2008 (Part 1 of 3, pp. 1-9). |
Comparative Testing of Hemostatic Dressings in a Severe Groin Hemorrhage, Trauma & Resuscitative Medicine Department, NMRC, Aug. 2008 (Part 2 of 3, pp. 10-19). |
Comparative Testing of Hemostatic Dressings in a Severe Groin Hemorrhage, Trauma & Resuscitative Medicine Department, NMRC, Aug. 2008 (Part 3 of 3, pp. 20-29). |
U.S. Appl. No. 13/682,085, filed Nov. 20, 2012, including prosecution history. |
Alam, et al., Comparative Analysis of Hemostatic Agents in a Swine Model of Lethal Groin Injury, Jun. 2003, The Journal of Trauma Injury, Infection, and Critical Care, vol. 54, No. 6, pp. 1077-1082. |
Dyer, A. et al. “Diffusion in heteroionic zeolites: part 1. Diffusion of water in heteroionics natrolites.” Microporous and Mesoporous Materials. 1998. pp. 27-38. vol. 21. |
Gielen, M., Solid State Organometallic Chemistry: Methods and Applications Physical Organometallic Chemistry, 1999, New York John Wiley & Sons, Ltd. (UK), V. 2, p. 156. |
Griffin, John H., “Role of surface in surface-dependent activation of Hageman factor (blood coagulation Factor XII)”, Proc. Natl. Acad. Sci. USA, 1978, vol. 75, No. 4, pp. 1998-2002. |
Hursey, et al., Bandage Using Molecular Sieves, Apr. 18, 2002, International Application Published Under the PCT, W0 02/30479 A1. |
IMA-EU, Kaolin, Oct. 2006, p. 1-2. |
Le Van Mao, Raymond et al. “Mesporous Aluminosilicates prepared from Zeolites by Treatment with Ammonium Fluorosilicate.” J. Mater. Chem. 1993. pp. 679-683. vol. 3, No. 6. |
Margolis, J., “Initiation of Blood Coagulation by Glass and Related Surfaces”, J. Physiol., 1957, vol. 137, pp. 35-109. |
The Merck Index; 1989, pp. 1596-1597, abstract 10021. |
Top, Ayben et al. “Silver, zinc, and copper exchange in a Na-clinoptilolite and resulting effect on antibacterial activity.” Applied Clay Science. 2004. pp. 13-19. vol. 27. |
Voet, Donald & Judith: “Molecular Physiology”, Biochemistry, p. 1087-1096, vol. 64, 1990, John Wiley & Sons. |
Wright, J.K. et al. “Thermal Injury Resulting from Application of a GranularMineral Hemostatic Agent.” The Journal of Trauma Injury, Infection, and Critical Care. 2004. pp. 224-230. vol. 57, No. 2. |
U.S. Appl. No. 12/352,513, filed Jan. 12, 2009, including prosecution history. |
U.S. Appl. No. 60/668,022, filed Apr. 4, 2005, including prosecution history. |
U.S. Appl. No. 60/708,206, filed Aug. 15, 2005, Including prosecution history. |
U.S. Appl. No. 60/902,738, filed Feb. 21, 2007, including prosecution history. |
U.S. Appl. No. 60/955,854, filed Aug. 14, 2007, including prosecution history. |
U.S. Appl. No. 11/054,918, filed Feb. 9, 2005, including prosecution history, including but not limited to Office Action dated Mar. 18, 2008. |
U.S. Appl. No. 12/555,876, filed Sep. 9, 2009, including prosecution history, including but not limited to Office Action dated Dec. 28, 2010 and Office Action dated May 27, 2011. |
U.S. Appl. No. 11/592,477, filed Nov. 2, 2006, including prosecution history, including but not limited to Office Action dated May 28, 2008, Office Action and dated Dec. 22, 2008 and Office Action dated Jun. 18, 2009. |
U.S. Appl. No. 11/643,673, filed Dec. 5, 2006, including prosecution history, including but not limited to Office Action dated May 12, 2008, Office Action dated Nov. 14, 2008, Office Action dated May 21, 2009 and Office Action dated Mar. 25, 2010. |
U.S. Appl. No. 11/590,427, filed Oct. 30, 2006, including prosecution history, including but not limited to Office Action dated Aug. 19, 2008, Office Action dated May 26, 2009, Office Action dated Jun. 7, 2010 and Office Action dated Apr. 5, 2011. |
U.S. Appl. No. 12/417,802, filed Apr. 3, 2009, including prosecution history, including but not limited to Office Action dated Jun. 11, 2010 and Office Action dated Jan. 25, 2011. |
U.S. Appl. No. 11/633,687, filed Dec. 4, 2006, including prosecution history, including but not limited to Office Action dated Sep. 4, 2008 and Office Action dated Jun. 12, 2009. |
U.S. Appl. No. 11/654,409, filed Jan. 17, 2007, including prosecution history, including but not limited to Office Action dated Mar. 30, 2010 and Final Office Action dated Oct. 25, 2010. |
U.S. Appl. No. 11/715,057, filed Mar. 6, 2007, including prosecution history, Including but not limited to Non-Final Rejection dated Aug. 20, 2008 and Final Rejection dated Apr. 2, 2009. |
U.S. Appl. No. 12/581,782, filed Oct. 19, 2009, including prosecution history, including but not limited to Office Action dated Mar. 16, 2011. |
U.S. Appl. No. 10/939,869, filed Sep. 13, 2004, including prosecution history, including but not limited to Office Action dated Feb. 8, 2008, Office Action date Sep. 17, 2008, Final Office Action dated Apr. 17, 2009, Final Office Action dated Apr. 1, 2010, Final Office Action date Dec. 12, 2010 and Office Action dated May 17, 2011. |
U.S. Appl. No. 11/082,716, filed Mar. 16, 2005, including prosecution history, including but not limited to Office Action dated Oct. 9, 2008. |
U.S. Appl. No. 11/303,607, filed Dec. 16, 2005, including prosecution history, including but not limited to Office Action dated Apr. 29, 2008 and Office Action dated Sep. 8, 2008. |
U.S. Appl. No. 11/404,126, filed Apr. 13, 2006, including prosecution history, including but not limited to Office Action dated Dec. 3, 2008, Office Action dated Dec. 21, 2009 and Notice of Abandonment dated Oct. 8, 2010. |
U.S. Appl. No. 11/586,986, filed Oct. 25, 2006, including prosecution history, including but not limited to Office Action dated Feb. 19, 2010 and Office Action dated Jun. 3, 2010. |
U.S. Appl. No. 10/939,687, filed Sep. 13, 2004, Including prosecution history. |
U.S. Appl. No. 11/023,869, filed Dec. 27, 2004, including prosecution history, including but not limited to Office Action dated May 12, 2008, Office Action dated Dec. 11, 2008, Office Action dated Jan. 26, 2010 and Office Action dated Sep. 16, 2010. |
U.S. Appl. No. 11/606,617, filed Nov. 29, 2006, including prosecution history, including but not limited to Office Action dated Jun. 12, 2009. |
U.S. Appl. No. 11/710,106, filed Feb. 22, 2007, including prosecution history, including but not limited to Office Action dated Oct. 1, 2010. |
U.S. Appl. No. 12/101,336, filed Apr. 11, 2008, including prosecution history, including but not limited to Office Action dated Mar. 22, 2010 and Notice of Abandonment dated Oct. 7, 2010. |
U.S. Appl. No. 12/101,346, filed Apr. 11, 2008, including prosecution history, including but not limited to Office Action dated Mar. 19, 2010 and Office Action dated Sep. 15, 2010. |
U.S. Appl. No. 11/634,531, filed Dec. 6, 2006, including prosecution history, including but not limited to Office Action dated Feb. 4, 2009, Office Action dated Sep. 4, 2009, Office Action dated Mar. 29, 2010, Final Office Action dated Oct. 5, 2010 and Office Action dated Jun. 23, 2011. |
U.S. Appl. No. 12/140,356, filed Jun. 17, 2008, including prosecution history, including but not limited to Office Action dated Sep. 28, 2010 and Office Action dated Mar. 21, 2011. |
U.S. Appl. No. 12/204,129, filed Sep. 4, 2008, including prosecution history, including but not limited to Office Action dated May 31, 2011. |
U.S. Appl. No. 11/544,238, filed Oct. 6, 2006, including prosecution history, including but not limited to Office Action dated May 29, 2009 and Office Action dated Jun. 25, 2010. |
U.S. Appl. No. 12/503,481, filed Jul. 15, 2009, including prosecution history, including but not limited to Office Action dated Dec. 27, 2010 and Office Action dated Jul. 5, 2011. |
U.S. Appl. No. 13/175,380 filed Jul. 1, 2011 including prosecution history. |
Curasorb Calcium Alginate Dressings information page, http://www.kendallhq.com/kendallhealthcare/pageBuilder.aspx?webPagelD=0&topicID=70966&xsl=xsl/productPagePrint.xsl (last accessed May 22, 2012). |
Hollister Wound Care Restor Calcium Alginate Dressing, Silver instruction manual and information booklet, available at http://hollisterwoundcare.com/files/pdfs/ifus/Restore907814B407ColorBreak.pdf (last accessed May 22, 2012). |
Medline Maxorb Extra AG Silver Alginate, http://www.medicaldepartmentstore.com/Medline-Maxorb-p/1560.htm (last accessed May 22, 2012). |
“Mastering the Art of Innovative Thinking,” (color brochure) FMC BioPolymer, 2001 FMC Corporation. |
Davis et al., 1H—NMR Study of Na Alginates Extracted from Sargassum spp. in Relation to Metal Biosorption, 110 Applied Biochemistry and Biotechnology 75 (2003). |
Hahn, Lynn: “High temperature 1H NMR to determine the relative amounts of guluronate and mannuronate in the sodium alginate sample”, Intertek, ASA, Analytical Report, Report No. 60665 v 1, dated May 6, 2012. |
Manugel® GMB alginate, FMC BioPolymer, Know how. It works.sm Product Specifications, 2011 FMC Corporation. |
U.S. Appl. No. 10/939,869, filed Sep. 13, 2004 including prosecution history, including but not limited to Non-Final Rejection dated Feb. 8, 2008, Non-Final Rejection dated Sep. 17, 2008, Final Rejection dated Apr. 17, 2009, Final Office Action dated Apr. 1, 2010, Final Office Action dated Dec. 12, 2010; Office Action dated May 17, 2011 and Notice of Allowance dated Mar. 23, 2012. |
U.S. Appl. No. 11/592,477, filed Nov. 2, 2006 including prosecution history, including but not limited to Non-Final Rejection dated May 28, 2008 and Final Rejection dated Dec. 22, 2008, Office Action dated Jun. 18, 2009 and Notice of Allowance dated Mar. 6, 2012. |
U.S. Appl. No. 11/634,531, filed Dec. 6, 2006, including prosecution history, including but not limited to Office Action dated Feb. 4, 2009; Office Action dated Sep. 4, 2009, Office Action dated Mar. 29, 2010; Final Office Action dated Oct. 5, 2010; Office Action dated Jun. 23, 2011; BPAI Notice of Appeal dated Apr. 17, 2012, Appeal No. 2012-007306. |
U.S. Patent Application No. 11/634,673, filed Dec. 5, 2006, including prosecution history, including but not limited to Office Action dated Nov. 14, 2008. |
U.S. Appl. No. 12/204,129, filed Sep. 4, 2008, including prosecution history, including but not limited to Office Action dated May 31, 2011, Nov. 17, 2011, and Notice of Abandonment dated Jun. 20, 2012. |
U.S. Appl. No. 12/555,876, filed Sep. 9, 2009, including prosecution history, including but not limited to Office Action dated Dec. 28, 2010, Office Action dated May 27, 2011, and Notice of Allowance dated Jun. 14, 2012. |
U.S. Appl. No. 13/115,699, filed May 25, 2011 including prosecution history, including but not limited to Notice of Allowance dated May 30, 2012. |
U.S. Appl. No. 13/526,431, filed Jun. 18, 2012 including prosecution history. |
EPO Extended Search Report, re EP Application No. 12163455, dated Sep. 12, 2012. |
Lin et al., Synthesis of Hybridized Polyacrylic Acid-Kaolin Material and Its Superwater Absorbent Performance, J. Huaqiao Univ. (Nat. Sci.) Mar. 2000. |
Long et al., Synthesis of Bentonite-superabsorbent Composite, J. Guilin Inst. Tech., Feb. 2004. |
U.S. Appl. No. 12/611,830, filed Nov. 3, 2009, including prosecution history. |
U.S. Appl. No. 13/593,310, filed Aug. 23, 2012, including prosecution history. |
U.S. Appl. No. 13/595,932, filed Aug. 27, 2012, including prosecution history. |
U.S. Appl. No. 13/598,381, filed Aug. 29, 2012, including prosecution history. |
Caloplast (Kaoline Poultrice), South African Electronic Package Inserts, Information presented by Malahyde Information Systems, Copyright 1996-1998, printed from home.intekom.com/pharm/allied/caloplst.html#INDICATIONS, two pages. |
International Preliminary Report and Written Opinion for Application No. PCT/US2007/023265, dated Sep. 29, 2009. |
International Preliminary Report and Written Opinion for PCT/US2004/029809, dated Mar. 13, 2006. |
International Preliminary Report and Written Opinion re PCT/US2006/004594, dated Aug. 14, 2007. |
International Preliminary Report and Written Opinion re PCT/US2008/006517, dated Nov. 24, 2009. |
International Preliminary Report and Written Opinion Report for Application No. PCT/US2008/060177, dated Oct. 13, 2009. |
International Report on Patentability and Written Opinion for Application No. PCT/US2008/003082, dated Sep. 29, 2009. |
PCT International Report on Patentability and Written Opinion re PCT/US2009/040256, dated Oct. 12, 2010. |
Vlok, Marie E.: “Kaoline poultice”, Manual of Nursing, vol. 1, Basic Nursing, revised ninth edition, p. 649. Copyright Juta & Co, Ltd., Lansdowne, South Africa, first published 1962. |
WoundStat found to be potentially hazardous, Army News, news from Iraq . . . , http://armytimes.com/news/2009/04/armLwoundstat—042009w/, posted Apr. 20, 2009, last accessed Apr. 20, 2009. |
U.S. Appl. No. 12/510,203, filed Jul. 27, 2009, including prosecution history, including but not limited to, Office Action dated Sep. 26, 2011 and Feb. 24, 2012. |
U.S. Appl. No. 12/611,830, filed Nov. 3, 2009, including prosecution history, including but not limited to Office Action dated Nov. 4, 2011 and Notice of Allowance dated Feb. 1, 2012. |
Dictionary of Traditional Chinese Medicine, “Astringents and Haemostatices,” The Commercial Press, Ltd., Apr. 1984 [ISBN 962 07 3051 8], pp. 216-217, total 4 pages. |
Hempen, et al., A Materia Medica for Chinese Medicine, Plants minerals and animal products, Churchill Livingston Elsevier, 2009, [ISBN 978 0 443 10094 9], pp. 832-833 (Halloysitum rubrum, Chi shi zi), total 5 pages. |
Hsu, et al. Orintal Materia Medica—a concise guide, pp. 310-311, 612-613, 32-34, total 12 pages. Oriental Healing Arts Institute, 1986. [ISBN 0 941 942 22 8]. |
Huang, Pharmacology of Chinese Herbs, Second Edition, p. 243 (Antidiarrheal Herbs), total 3 pages. CRC Press 1999. [ISBN 0 8493 1665 0]. |
Li, et al. Chinese Materia Medica—Combinations and Applications, Donica Publishing Ltd., 2002, [ISBN 1 901149 02 1], p. 622 (Ch. 18 Herbs for Promoting Astriction), total 5 pages. |
Soine et al., Roger's Inorganic Pharmaceutical Chemistry, Lea & Febiger 1967, p. 462-463 (Aluminum and Aluminum Compounds), [QV744 S683r 1967] total 5 pages. |
Wu, Jing-Nuan, “An Illustrated Chinese Materia Medica,” Oxford University Press, Inc. 2005 (13 pages). |
Xinrong, Traditional Chinese Medicine, A Manual from A-Z, Symptoms, Therapy and Herbal Remedies, [ISBN 3 540 42846 1], p. 470 (total 3 pages), Springer-Verlag Berlin Heidelberg 2003. |
Yanchi, The Essential Book of Traditional Chinese Medicine, vol. 2: Clinical Practice, p. 155-157 (Traditional Chinese Prescriptions), , 142-143 (Chinese Medicinal Herbs) total 8 pages. [ISBN 0 231 06518 3 9v.2] 1988. |
U.S. Appl. No. 13/759,963, filed Feb. 5, 2013, including prosecution history. |
Webster's Dictionary definition of “expose” (1993). |
U.S. Appl. No. 13/911,616, filed Jun. 6, 2013, including prosecution history. |
U.S. Appl. No. 13/922,115, filed Jun. 19, 2013, including prosecution history. |
Connor, William E.: “The Acceleration of Thrombus Formatin by Certain Fatty Acids,” Journal of Clinical Investigation, vol. 41, No. 6, 1962. |
Hubbard, et al.: “Ionic charges of glass surfaces and other materials, and their possible role in the coagulation of blood,” Journal of Applied Physiology, Mar. 1, 1960, vol. 15, No. 2, pp. 265-270. |
Ross, et al., “The Kaolin Minerals,” J. Amer. Ceramic Soc., vol. 13, issue 3, pp. 151 to 160, Mar. 1930. |
Alam, et al., Application of a Zeolite Hemostatic Agent Achieves 100% Survival in a Lethal Model of Complex Groin Injury in Swine, May 2004, The Journal of Trauma Injury, Infection, and Critical Care, vol. 56, pp. 974-983. |
Aldrich—Handbook of Fine Chemicals and Laboratory Equipment, 2000-2001, pp. 1177-1178. |
Analgesics and Anti-inflammatory agents 2004, retrieved from the internet on May 26, 2010, URL: http://web.archive.org/web/20040904151322/http://faculty.weber.edu/ewalker/Medicinal—Chemistry/topics/Analgesia—antiinflam/Analgesics—anti-inflamitory.htm. |
Angeloni, V., M.D.: “How to care for your wound.”, Heartland Dermatology & Skin Cancer P. C., copyright 2001, V. Angeloni MD. |
Army halts use of new first aid item to study more, Seattle PI, Dec. 24, 2008. |
Army halts use of WoundStat, http://stripes.com, Apr. 23, 2009. |
Army pulls anti clotting agent after Fort Sam study finds threat, MySanAntonio Military, Dec. 24, 2008. |
Baker, Sarah E. et al., Controlling Bioprocesses with Inorganic Surfaces: Layered Clay Hemostatic Agents, Department of Chemistry and Biochemistry, University of California, Santa Barbara, American Chemical Association 2007, 19, pp. 4390-4392 (3 pages total). |
Basadonna, G., et al.: “A novel kaolin coated surgical gauze improves hemostasis both in vitro and in vivo”, Journal of Surgical Research, vol. 144, No. 2, Feb. 2008, p. 440, XP002534658, abstract. |
Bethesda, MD, TraumaCure, Life-saving News for Battlefield Soldiers & Wounded Civilians FDA Clears Product to Stop Severe Bleeding, Sep. 10, 2007. |
Butenas—Mechanism of factor VIIa-dependent coagulation in hemophilia blood, Hemostasis, Thrombosis, and Vascular Biology, Blood, Feb. 1, 2002—vol. 99, No. 3. |
Carraway, et al., Comparison of a new mineral based hemostatic agent to a commercially available granular zeolite agent for hemostasis in a swine model of lethal extremity arterial hemorrhage, Resuscitation vol. 78, Issue 2, Aug. 2008. |
Clay makers (raw materials) retrieved from the internet on Mar. 15, 2010, URL: http://web.archive.org/web/20020609175053/http://www.claymaker.com/ceramic—central/info/raw—clays.htm (year 2002, pp. 104). |
Comparative Testing of Hemostatic Dressings in a Severe Groin Hemorrhage, Trauma & Resuscitative Medicine Department, NMRC, presented at the 2008 annual meeting of Advanced Technology Applications for Combat Casualty Care (ATACCC). |
EPO Partial Search Report dated Jun. 27, 2006 re EP App. No. 05445078.8. |
EPO Search Report and Opinion, re EP 1 797 850, dated May 11, 2007. |
EPO Search Report for EP 05020602, dated Jul. 6, 2006. |
EPO Search Report for EP 06123557, dated Feb. 29, 2008. |
EPO Search Report for EP 06126082, dated May 11, 2007. |
EPO Supplemental Search Report re EP 1 663 090, dated Jun. 22, 2010. |
European, Extended Search Report, re Application No. 10190569.3, dated Jan. 25, 2011. |
Fruijtier-Polloth, “The safety of synthetic zeolites used in detergents”, Arch Toxicol (2009) 83:23-25. |
Galan, et al.: “Technical properties of compound kaolin sample from griva (Macedonia, Greece)”, Applied Clay Science 1996 10:477-490. |
Gibbar-Clements, et al.: “The Challenge of Warfarin Therapy”, JSTOR: The American Journal of Nursing,vol. 100, No. 3 (Mar. 2000), pp. 38-40. |
Griffin, J. H.: “Role of surface in surface-dependent activation of Hageman factor (blood coagulation Factor XII)”, Proc. Natl. Acad. Sci, USA, vol. 75, No. 4, pp. 1998-2002, Apr. 1978 Medical Sciences. |
HemCon Medical Technologies Inc. 501(k) Summary, GhitoGauze, Mar. 20, 2009. |
International Search Report for Application No. PCT/US2004/029812, dated Jun. 14, 2005. |
International Search Report for Application No. PCT/US2006/004594, dated Nov. 3, 2006. |
International Search Report for Application No. PCT/US2006/012487, dated Sep. 12, 2006. |
International Search Report for Application No. PCT/US2007/016509, dated Feb. 8, 2008. |
International Search Report for Application No. PCT/US2007/023265, dated Sep. 17, 2009. |
International Search Report for Application No. PCT/US2008/003082, dated Sep. 24, 2009. |
International Search Report for Application No. PCT/US2008/060177, dated Jun. 22, 2009. |
International Search Report for Application No. PCT/US2008/075191, dated Oct. 6, 2008. |
International Search Report for PCT/US2004/029809, dated Feb. 24, 2005. |
International Search Report for PCT/US2005/046700, dated Jul. 6, 2006. |
James, “Silver Copper Zeolite Guinea Pig Sensitization Study—Beuhler Method”, Data Evaluation Report dated Oct. 3, 1989. |
Kheirabadi, Army Assessment of New Hemostatic Products Suitable for Treating Combat Wounds, US Army Institute of Surgical Research, Aug. 11, 2008. |
Kheirabadi, et al., The Journal of Trauma Injury, Infection, and Critical Care, Comparison of New Hemostatic Granules/Powders with Currently Deployed Hemostatic Products in a Lethal model of Extremity Arterial Hemorrhage in Swine, Feb. 2009, pp. 316-328. |
Kheirabadi, Final Report, Title: Assessment of Efficacy of New Hemostatic Agents in a Model of Extremity Arterial Hemorrhage in Swine, U.S. Army Institute of Surgical Research, Ft. Sam Houston, TX 78234, Mar. 4, 2008. |
Kovzun, I. G., et al.: “Application of nanosize clay-mineral systems in the complex therapy for hemophilia “A” patients”, Database HCAPLUS [online], XP002534657, retrieved from STN Database accession No. 2009:502758 abstract & Nanosistemi, Nanomateriali, Nanotekhnologii, vol. 6, No. 2, 2008. |
Macrina, VCU's Research Enterprise, Structure and Resources, Oct. 23, 2008. |
Margolis, “Initiation of Blood Coagulation by Glass and Related Surfaces”, J. Physiol. (1957) 137, 95-109. |
Okada, et al.: “Preparation of zeolite-coated cordierite honeycombs prepared by an in situ crystallization method”, Science and Technology of Advanced Materials 2004 5:479-484. |
O'Reilly et al.: “Studies on Coumarin Anticoagulant Drugs—lnitiaion of Warfarin Therapy Without a Loading Dose”, Circulation by the American Heart Association, http://circ.ahajournals.org, 1968, 38, 169-177. |
Ore-Medix, Traumastat Hemostatic Bandage, Aug. 7, 2008. |
PCT International Search Report re Application No. PCT/US2010/041741, dated Nov. 26, 2010. |
PCT International Search Report re PCT/US2009/040256, dated Aug. 4, 2009. |
Permanent suspension of Woundstat use, https://email.z-medica.com, Apr. 17, 2009. |
Reprinted related contents of U.S. Abstract regarding QuickClot Combat Gauze (reprinted on May 21, 2009). |
Reprinted related contents of U.S. Alaract regarding QuikClot CombatGauze, Sep. 2008. |
Sadler et al.: “Biochemstry and Genetics of Van Willebrand Factor”, Annual Review of Biochemistry; 1998. 67:395-424. |
Scott Sackinger's Medical Devices Professional Summary dated Mar. 2009. |
Sinter. (2004). In the New Penguin Dictionary of Science. London: Penguin. Retrieved May 7, 2009, from http://www.credoreference.com/entry/7463549/. |
Tactical Combat Casualty Care Guidelines, Feb. 2009. |
TraumaCure, Innovative Wound Care Products for Wound Care Solutions, Apr. 24, 2009. |
Vitrify—(2001). In Chambers 21s5t Century Dictionary. London. Chambers Harrap. Retrieved May 7, 2009, from http://www.credoreference.com/entry/1236485/. |
Wagner, Holly, “Topical Oxygen Helps Hard-To-Heal Wounds Heal Faster and Better,” Jan. 28, 2003, obtained from http://researchnews.osu.edu/archive/oxvwound.htm. |
Ward, et al., The Journal of Trauma Injury, Infection, and Critical Care, Comparison of a New Hemostatic Agent to Current Combat Hemostatic Agents in a Swine Model of Lethal Extremity Arterial Hemorrhage, Aug. 2007, pp. 276-284. |
Wound Stat, http://shadowspear.com/vb/showthread.php?t=16586 dated Dec. 22, 2008, last accessed Apr. 16, 2009. |
WoundStat found to be potentially hazardous, Army News, news from Iraq . . . , http://armytimes.com/news/2009/04/army—woundstat—042009w/, posted Apr. 20, 2009, last accessed Apr. 20, 2009. |
Wright, J. Barry et al.: “Wound management in an era of increasing bacterial antibiotic resistance: A role for topical silver treatment”, American Journal of Infection Control, vol. 26 (6), 1998, pp. 572-577. |
Z-Medica Corporation 510(k) Summary, QuikClot eX, Oct. 4, 2007. |
U.S. Appl. No. 12/352,513, filed Jan. 12, 2009 including prosecution history. |
U.S. Appl. No. 10/939,687, filed Sep. 13, 2004 including prosecution history, including but not limited to Non-Final Rejection dated Oct. 16, 2006, Final Rejection dated May 24, 2007, Non-Final Rejection dated Sep. 6, 2007, Final Rejection dated Nov. 28, 2007 and Examiner's Answer to Appeal Brief. |
U.S. Appl. No. 11/054,918, filed Feb. 9, 2005 including prosecution history, including but not limited to Non-Final Office Rejection dated Mar. 18, 2008, Final Rejection dated Sep. 16, 2008 and Non-Final Rejection dated Mar. 9, 2009. |
U.S. Appl. No. 12/204,129, filed Sep. 4, 2008, including prosecution history, including but not limited to Office Action dated May 31, 2011 and Nov. 17, 2011. |
U.S. Appl. No. 12/510,203, filed Jul. 27, 2009, including prosecution history, including but not limited to Office Action dated Sep. 26, 2011. |
U.S. Appl. No. 10/939,869, filed Sep. 13, 2004, including prosecution history, including but not limited to Final Office Action dated May 17, 2011. |
U.S. Appl. No. 12/140,356, filed Jun. 17, 2008, including prosecution history, including but not limited to Final Office Action dated Mar. 21, 2011. |
U.S. Office Action re U.S. Appl. No. 11/398,161 dated Apr. 30, 2008. |
U.S. Appl. No. 11/584,079, filed Oct. 20, 2006, including prosecution history, including but not limited to Office Action dated Apr. 6, 2009. |
U.S. Appl. No. 11/634,673, filed Dec. 5, 2006, including prosecution history, including but not limited to Office Action dated Nov. 14, 2008. |
U.S. Appl. No. 12/417,802, filed Apr. 3, 2009, including prosecution history, including but not limited to Office Action dated Jun. 11, 2010. |
Number | Date | Country | |
---|---|---|---|
20120070470 A1 | Mar 2012 | US |
Number | Date | Country | |
---|---|---|---|
61385388 | Sep 2010 | US |